| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8940751 | European Urology Oncology | 2018 | 8 Pages |
Abstract
In this article, we found that there is currently insufficient evidence to support the use of oral antiangiogenics in nonmetastatic renal cell carcinoma after nephrectomy. In addition, the use of oral antiangiogenics was associated with a 2.7-fold higher rate of significant side effects compared to placebo.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Mohamad B. Sonbol, Belal Firwana, Talal Hilal, Zhen Wang, Diana Almader-Douglas, Richard W. Joseph, Thai H. Ho,